FDC Limited

NSE FDC.NS

FDC Limited EBITDA for the year ending March 31, 2024: USD 52.77 M

FDC Limited EBITDA is USD 52.77 M for the year ending March 31, 2024, a 44.18% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

FDC Limited EBITDA for the year ending March 31, 2023 was USD 36.60 M, a -15.73% change year over year.
FDC Limited EBITDA for the year ending March 31, 2022 was USD 43.43 M, a -25.86% change year over year.
FDC Limited EBITDA for the year ending March 31, 2021 was USD 58.58 M, a 22.00% change year over year.
FDC Limited EBITDA for the year ending March 31, 2020 was USD 48.02 M, a 22.06% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NSE: FDC.NS

FDC Limited

CEO	Mr. Ameya Ashok Chandavarkar
IPO Date	July 1, 2002
Location	India
Headquarters	C/3, Skyvistas
Employees	6,659
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.

Key trends

Past 5 years